SEC Comment Letter 0000000000-22-013432 to NovaBay Pharmaceuticals, Inc. (NBY) (CIK 0001389545) (NBY)
NovaBay Pharmaceuticals, Inc. (NBY) (CIK 0001389545)
Date: Dec. 13, 2022 · CIK: 0001389545 · Accession: 0000000000-22-013432
AI Filing Summary & Sentiment
File numbers found in text: 333-268738
Letter
United States securities and exchange commission logo December 13, 2022 Justin M. Hall Chief Executive Officer NovaBay Pharmaceuticals, Inc. 2000 Powell Street, Suite 1150 Emeryville, CA 94608 Re:NovaBay Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed December 9, 2022 File No. 333-268738 Dear Justin M. Hall: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Christine Westbrook at 202-551-5019 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Abby E. Brown, Esq.
Show Raw Text
United States securities and exchange commission logo
December 13, 2022
Justin M. Hall
Chief Executive Officer
NovaBay Pharmaceuticals, Inc.
2000 Powell Street, Suite 1150
Emeryville, CA 94608
Re:NovaBay Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed December 9, 2022
File No. 333-268738
Dear Justin M. Hall:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Christine Westbrook at 202-551-5019 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Abby E. Brown, Esq.